Alere Company Profile (NYSE:ALR)

About Alere (NYSE:ALR)

Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:ALR
  • CUSIP: 01449J10
  • Web:
  • Market Cap: $4.47 billion
  • Outstanding Shares: 87,577,000
Average Prices:
  • 50 Day Moving Avg: $50.45
  • 200 Day Moving Avg: $49.25
  • 52 Week Range: $34.41 - $51.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 36.42
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.32 billion
  • Price / Sales: 1.92
  • Book Value: $13.20 per share
  • Price / Book: 3.86
  • EBITDA: $261.2 million
  • Net Margins: -16.86%
  • Return on Equity: -33.39%
  • Return on Assets: -6.72%
  • Debt-to-Equity Ratio: 2.43%
  • Current Ratio: 2.04%
  • Quick Ratio: 1.54%
  • Average Volume: 1.52 million shs.
  • Beta: 0.21
  • Short Ratio: 1.85

Frequently Asked Questions for Alere (NYSE:ALR)

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc (NYSE:ALR) posted its earnings results on Friday, November, 4th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.54 by $0.35. The business had revenue of $582 million for the quarter, compared to analyst estimates of $605.50 million. Alere had a negative return on equity of 33.39% and a negative net margin of 16.86%. The firm's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same period last year, the company posted ($0.10) EPS. View Alere's Earnings History.

When will Alere make its next earnings announcement?

Alere is scheduled to release their next quarterly earnings announcement on Friday, November, 3rd 2017. View Earnings Estimates for Alere.

Where is Alere's stock going? Where will Alere's stock price be in 2017?

5 analysts have issued 1-year price targets for Alere's stock. Their predictions range from $42.00 to $51.00. On average, they expect Alere's stock price to reach $48.00 in the next twelve months. View Analyst Ratings for Alere.

What are analysts saying about Alere stock?

Here are some recent quotes from research analysts about Alere stock:

  • 1. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (8/17/2017)
  • 2. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)

Who are some of Alere's key competitors?

Who are Alere's key executives?

Alere's management team includes the folowing people:

  • Gregg J. Powers, Independent Chairman of the Board
  • Namal Nawana, President, Chief Executive Officer, Director
  • James F. Hinrichs, Chief Financial Officer, Executive Vice President
  • Daniella Cramp, Global President - Cardiometabolic Business Unit
  • Sanjay Malkani, Global President - Toxicology
  • Avi Pelossof, Global President - Infectious Disease Business Unit
  • Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
  • Robert Hargadon, Senior Vice President - Global Human Resources
  • John Bridgen Ph.D., Senior Vice President - Business Development
  • Mark Gladwell, Senior Vice President - Global Operations

How do I buy Alere stock?

Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alere's stock price today?

One share of Alere stock can currently be purchased for approximately $50.99.

MarketBeat Community Rating for Alere (NYSE ALR)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alere (NYSE:ALR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $48.00 (5.86% downside)
Consensus Price Target History for Alere (NYSE:ALR)
Price Target History for Alere (NYSE:ALR)
Analysts' Ratings History for Alere (NYSE:ALR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Canaccord GenuityReiterated RatingHold$51.00LowView Rating Details
6/1/2017Jefferies Group LLCReiterated RatingHold$51.00MediumView Rating Details
5/24/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/15/2017Craig HallumDowngradeBuy -> HoldLowView Rating Details
11/4/2016Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$45.00 -> $42.00N/AView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$56.00N/AView Rating Details
2/2/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/5/2015WedbushLower Price TargetNeutral$43.00 -> $39.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Alere (NYSE:ALR)
Earnings by Quarter for Alere (NYSE:ALR)
Earnings History by Quarter for Alere (NYSE ALR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 16$0.54$0.19$605.50 million$582.00 millionViewN/AView Earnings Details
9/6/2016Q216$0.58($0.46)$621.95 million$611.10 millionViewN/AView Earnings Details
8/17/2016Q116$0.56($0.18)$578.00 millionViewN/AView Earnings Details
8/8/2016Q415$0.58($0.28)$662.04 million$623.00 millionViewN/AView Earnings Details
11/4/2015Q315$0.55$0.49$646.29 million$602.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.49$625.67 million$629.00 millionViewN/AView Earnings Details
5/5/2015Q115$0.49$0.57$612.93 million$610.40 millionViewN/AView Earnings Details
2/10/2015Q414$0.63$0.61$698.56 million$666.90 millionViewN/AView Earnings Details
10/28/2014Q314$0.52$0.48$743.30 million$736.20 millionViewN/AView Earnings Details
8/4/2014Q214$0.58$0.43$747.55 million$738.30 millionViewN/AView Earnings Details
4/29/2014Q114$0.55$0.55$738.70 million$716.60 millionViewN/AView Earnings Details
2/6/2014Q413$0.56$0.62$770.70 million$772.30 millionViewN/AView Earnings Details
10/29/2013Q313$0.53$0.59$737.66 million$753.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.48$0.64$720.24 million$764.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.51$0.53$727.66 million$739.20 millionViewN/AView Earnings Details
2/15/2013Q4 2012$0.57$0.55$714.75 million$755.80 millionViewN/AView Earnings Details
11/8/2012Q312$0.53$0.43$690.76 million$691.40 millionViewN/AView Earnings Details
8/8/2012$0.53($0.23)ViewN/AView Earnings Details
4/30/2012$0.67$0.77ViewN/AView Earnings Details
2/8/2012$0.71$0.74ViewN/AView Earnings Details
10/26/2011$0.57$0.67ViewN/AView Earnings Details
7/27/2011$0.58$0.46ViewN/AView Earnings Details
4/27/2011$0.61$0.61ViewN/AView Earnings Details
2/17/2011$0.66$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alere (NYSE:ALR)
Current Year EPS Consensus Estimate: $0.80 EPS
Next Year EPS Consensus Estimate: $1.40 EPS


Dividend History for Alere (NYSE:ALR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alere (NYSE:ALR)
Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 89.33%
Insider Trades by Quarter for Alere (NYSE:ALR)
Institutional Ownership by Quarter for Alere (NYSE:ALR)
Insider Trades by Quarter for Alere (NYSE:ALR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016Melissa GuerdanSVPSell2,500$54.00$135,000.00View SEC Filing  
11/13/2015Robert Bernard HargadonSVPBuy1,000$38.99$38,990.00View SEC Filing  
11/12/2015James F HinrichsCFOBuy10,000$39.97$399,700.00View SEC Filing  
9/3/2015Mark GladwellVPSell2,651$52.27$138,567.77View SEC Filing  
9/3/2015Melissa GuerdanSVPSell5,135$52.00$267,020.00View SEC Filing  
9/1/2015Melissa GuerdanSVPSell5,000$50.48$252,400.00View SEC Filing  
8/31/2015Mark GladwellVPSell27,513$52.23$1,437,003.99View SEC Filing  
8/14/2015Sanjay MalkaniInsiderSell31,460$54.60$1,717,716.00View SEC Filing  
6/8/2015Sanjay MalkaniInsiderSell24,331$50.87$1,237,717.97View SEC Filing  
6/4/2015Sanjay MalkaniInsiderSell15,669$52.18$817,608.42View SEC Filing  
6/1/2015John BridgenSVPSell7,500$51.19$383,925.00View SEC Filing  
4/6/2015Melissa GuerdanSVPSell2,500$50.00$125,000.00View SEC Filing  
3/23/2015Melissa GuerdanSVPSell13,476$48.35$651,564.60View SEC Filing  
3/17/2015John BridgenSVPSell25,000$48.53$1,213,250.00View SEC Filing  
3/16/2015Carla FlakneCAOSell8,500$48.99$416,415.00View SEC Filing  
1/16/2015Carla FlakneCAOSell10,000$42.45$424,500.00View SEC Filing  
12/24/2014Don DudekDirectorBuy40,000$0.01$500.00
12/11/2014John BridgenSVPSell50,000$37.07$1,853,500.00View SEC Filing  
8/15/2014Dave TeitelCFOSell10,000$35.07$350,700.00View SEC Filing  
8/15/2013Dave TeitelCFOSell10,000$31.73$317,300.00View SEC Filing  
8/5/2013Michael Lester CottonInsiderSell12,500$33.82$422,750.00View SEC Filing  
5/31/2013Michael Lester CottonInsiderSell8,750$25.86$226,275.00View SEC Filing  
3/5/2013John QuelchDirectorSell20,220$23.49$474,967.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alere (NYSE:ALR)
Latest Headlines for Alere (NYSE:ALR)
DateHeadline logoAlere (ALR) vs. Its Competitors Head to Head Survey - October 15 at 4:28 AM logoAlere Inc. (ALR) Given Consensus Recommendation of "Hold" by Brokerages - October 12 at 4:46 AM logoContrasting Hansen Medical (HNSN) & Alere (ALR) - October 7 at 6:30 PM logoAlere (ALR) & Its Peers Head-To-Head Comparison - October 7 at 4:18 AM logoAlere Inc. -- Moody's to withdraw Alere's ratings following debt redemption - October 5 at 6:13 PM logoAlere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular Test - October 2 at 3:36 PM logoAlere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test - October 2 at 3:36 PM logoAlere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test - October 2 at 3:36 PM logoCorporate News Blog - Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign Acquisitions - October 2 at 3:36 PM logoFDA clears Alere's second-generation flu test - October 2 at 11:25 AM logoAlere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test - - October 2 at 7:31 AM logoAlere Reaches Settlement With SEC - September 30 at 2:13 PM logoAlere (ALR) Reports U.S. DOJ has Ended Investigation Into Sales, Sales Practices and Dealings with Certain 3rd Parties - September 30 at 2:13 PM logoAbbott (ABT) Se to Close Alere (ALR) Takeover on October 3 - - September 29 at 8:20 PM logoAlere Announces Agreement In Principle To Settle With U.S. DoJ - September 29 at 3:19 PM logoAlere Announces the U.S. Department of Justice Closes Investigation - September 29 at 3:19 PM logoAlere Reaches Analyst Target Price - September 29 at 3:19 PM logoAlere Agrees To Pay More Than $13 Mln To Settle SEC Accounting Fraud Charges - September 28 at 9:20 PM logoAbbott wins U.S. antitrust approval to buy Alere with conditions - September 28 at 4:17 PM logoAlere to divest two product lines to get FTC signoff on Abbott merger; shares up 4% - September 28 at 3:23 PM logoAlere to pay $13M to settle SEC inquiry into revenue recognition issues - September 28 at 12:24 PM logoAlere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017 - September 22 at 2:43 PM logoAlere Inc. (ALR) Stock Rating Reaffirmed by Canaccord Genuity - September 20 at 2:38 PM logoQuidel Corp (QDEL) Gains After Revised Deal on Alere's (ALR) BNP ... - - September 19 at 3:46 PM logoAlere Inc. Declares Cash Dividend on its Series B Convertible ... - PR Newswire (press release) - September 19 at 3:46 PM logoAlere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017 - September 19 at 3:46 PM logoHere's Why Quidel Corporation Stock Is Popping Today - September 19 at 3:46 PM logoAlere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott - September 18 at 9:11 PM logoMid-Day ETF Update: ETFs, Stocks Higher as Major Indices Reach Fresh All-Time Highs - September 18 at 4:10 PM logoMedical Research Stock Performance Review -- Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher Scientific - September 18 at 4:10 PM logoAlere Inc. (ALR) Given Consensus Recommendation of "Hold" by Analysts - September 17 at 4:40 AM logoALERE INVESTIGATION INITIATED by Former Louisiana Attorney ... - Business Wire (press release) - September 16 at 3:33 PM logoHead to Head Comparison: Fulgent Genetic (FLGT) vs. Alere (ALR) - September 11 at 1:08 PM logoALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ... - September 9 at 2:12 AM logoAlere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : September 8, 2017 - September 8 at 4:06 PM logoAlere (ALR) versus Boston Scientific Corporation (BSX) Head-To-Head Survey - September 6 at 12:22 PM logoALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the ... - Business Wire (press release) - September 2 at 2:25 AM logoALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALR - September 2 at 2:25 AM logoAlere Inc. (ALR) Sees Large Growth in Short Interest - August 31 at 1:46 AM logoNew Strong Sell Stocks for August 28th - August 28 at 3:51 PM logoETFs with exposure to Alere, Inc. : August 25, 2017 - August 25 at 5:21 PM logoAlere Inc. (ALR) Receives Average Rating of "Hold" from Analysts - August 23 at 4:44 AM logoAlere, Inc. :ALR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 - August 16 at 3:48 PM logoSee what the IHS Markit Score report has to say about Alere Inc. - August 12 at 3:34 PM logoSee what the IHS Markit Score report has to say about Alere Inc. - August 12 at 3:34 PM logoAlere Provides Notice to Holders of Series B Convertible Perpetual Preferred Stock - August 11 at 4:16 PM logoEARNINGS SUMMARY: Details of Alere Inc. Q2 Earnings Report - August 4 at 9:09 PM logoAlere Enters Oversold Territory (ALR) - August 4 at 9:09 PM logoAlere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : August 4, 2017 - August 4 at 4:07 PM logoAlere Reports Second Quarter 2017 Financial Results - August 3 at 4:45 PM



Alere (ALR) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.